The findings arrive after a swirl of regulatory uncertainty surrounding the trivalent (three-strain) vaccine, mRNA-1010.
Combriax demonstrates strong immunogenicity across age groups, exceeding comparator vaccines for multiple influenza strains ...
Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to ...
For adults aged 50 years or older, an investigational messenger RNA (mRNA)-based vaccine (mRNA-1010) is superior to ...
Increasing influenza vaccination coverage to 70% could prevent more than 30,000 pediatric hospitalizations and 123 pediatric ...
An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.
The first ever avian influenza vaccine recently started trials in the UK. This marks a milestone in the prevention of bird flu infections in humans. The vaccine targets the H5N1 flu strain, which ...
Countries that invested in seasonal influenza vaccination programs for health workers prior to the COVID-19 pandemic were significantly better positioned to deploy COVID-19 vaccines rapidly and ...
The numbers are in from the first year of required reporting of flu vaccination coverage among nursing home residents, and, ...
A new study will explore the effects of a nasal spray flu vaccine on children's immune systems, aiming to boost future ...
Countries that invested in seasonal influenza vaccination programs for health workers prior to the COVID-19 pandemic were ...
Experts are urging Australians to roll up their sleeves as soon as the 2026 influenza vaccine becomes available, following last year's low vaccine uptake and high caseload. It comes as a fast-moving ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results